News & Events

News Releases
NEW YORK , Sept. 18, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that Ivan Bergstein , M.D., Stemline’s CEO, will present at the

Additional Formats

NEW YORK , Sept. 05, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that Ivan Bergstein , M.D., Stemline’s CEO, will present at the

Additional Formats

NEW YORK , Aug. 09, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that Ivan Bergstein , M.D., Stemline’s CEO, will present at the 2019

Additional Formats

NEW YORK , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc . (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing innovative oncology therapeutics, today announced the pricing of an underwritten public offering

Additional Formats

NEW YORK , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) , a commercial -stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing innovative oncology therapeutics, today announced that it intends to offer and sell, subject to

Additional Formats